Showing 4781-4790 of 7028 results for "".
- SkinGPT Uses AI to Visualize Long-Term Skincare Benefitshttps://practicaldermatology.com/news/skin-gpt-uses-ai-to-visualize-long-term-skincare-benefits/2461670/Haut.AI is incorporating its new generative AI tech for modeling skin conditions over time. SkinGPT uses AI to create synthetic images and apply skin conditions to input image data. SkinGPT enables users to upload their photos and apply AI to
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t
- Building a Better Sunscreen: Is Rosmarinic Acid the Key?https://practicaldermatology.com/news/building-a-better-sunscreen-is-rosmarinic-acid-the-key/2461646/Rosmarinic acid may enhance sunscreen efficacy without increasing concentration of conventional UV filters, a new study in Cosmetics suggests. When 0.1% Rosmarinic acid an active antioxidant was added
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- AbbVie Enters Doc Film Biz: Company Releases New Film on Life with Eczemahttps://practicaldermatology.com/news/abbvie-enters-doc-film-biz-company-releases-new-film-on-living-with-eczema/2461609/AbbVie is releasing a new documentary film, “Under My Skin: Untold Stories of Life with Eczema,” which debuted at South by Southwest 2023 in Austin, Texas. The film, directed by Redglass Pictures, features the physical and emotional stories of three ind
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Report: More Physician Turnover, Use of Extenders in Private Equity-backed Dermatology Practiceshttps://practicaldermatology.com/news/report-more-physician-turnover-use-of-extenders-in-private-equity-backed-dermatology-practices/2461502/There’s more physician turnover and greater reliance on physician assistants in dermatology practices that sold to private equity, a new study shows. In the study of 213 private equity-acquired practices in dermatology, ophthalmology, and gastroenterology and 995 physic
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- MyHealthTeam and Arcutis Biotherapeutics Launch Social Network for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/myhealthteam-and-arcutis-biotherapeutics-launch-social-network-for-people-living-with-seborrheic-dermatitis/2461454/
- Almirall Joins Project Aimed at Giving Clinical Trial Data Back to Study Participantshttps://practicaldermatology.com/news/almirall-joins-project-aimed-at-giving-clinical-trial-data-back-to-study-participants/2461446/Almirall is participating in FACILITATE (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem), a patient-driven Innovative Medicines Initiative (IMI) project that aims to create a framework for access and reutilization of clinical tria